AzTrials
AzTrials

Breast NeoplasmsNCT07644910

Nudging Preventive Screening Via Message Framing and Bundling

A study testing Basic cancer screening message, Basic chronic disease test message and Basic combined message in people with Breast Neoplasms and Uterine Cervical Neoplasms, run by University of Chile.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This study is a randomized controlled field experiment embedded in the medical institution Early Diagnosis Program in Chile. Participants with two exams pending (a cancer screening test and a chronic disease test for diabetes and dyslipidemia) will be randomly assigned across a 3 × 3 factorial design: three message… Read more about this study

Who is it for?
Ages 21 to 74 years
What is being tested?
Basic cancer screening message, Basic chronic disease test message and Basic combined message
Could I receive a placebo?
No, everyone receives an active treatment
How many people
235,000 participants
Where
No sites listed yet
Study dates
8 Jun 2026to 8 Dec 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 74 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Has at least one pending cancer screening (breast, colorectal, cervical, or prostate) within the contact window, as determined by the medical institution
  • Aged 21 to 74 years
  • Has a valid phone number on file
  • Eligibility is determined operationally before randomization (ex-ante)

Who cannot join

  • Participants whose WhatsApp message was not successfully delivered, as reported by the third-party software used by the medical institution.

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Daniel Schwartz Associate Professor, Department of Industrial Engineering, Ph.D. Behavioral Decision contact

+56979984165

daschwar@dii.uchile.cl

About this study

Official title: The Effect of Message Framing and Screening Bundling on Preventive Screening Engagement: A Randomized Field Experiment

This study is a randomized controlled field experiment embedded in the medical institution Early Diagnosis Program in Chile. Participants with two exams pending (a cancer screening test and a chronic disease test for diabetes and dyslipidemia) will be randomly assigned across a 3 × 3 factorial design: three message framing conditions (Basic, Risk/Importance, Peace of Mind) crossed with three exam-type conditions (cancer screening only, chronic disease test only, or both exams). Participants with only a cancer screening pending will be assigned to the 3 framing conditions and be encouraged to get the cancer screening.

In both cases, participants are assigned to each experimental arm at twice the rate of an additional arm receiving the standard message currently used by the medical institution. This standard-message arm is included for operational purposes, is not part of the pre-specified analyses, and is thus not described in the "Arms and Intervention" section (or counted for "number of arms").

Read the detailed description

The investigators will conduct a randomized controlled trial in the domain of preventive care engagement. Participants with two exams pending (a cancer screening test and a chronic disease test for diabetes and dyslipidemia) will be randomly assigned to a 3 × 3 factorial design. The first factor manipulates message framing, randomly assigning participants to receive either (i) a standard Whatsapp message, (ii) a Whatsapp message emphasizing age-related health risks and the importance of early detection, or (iii) a message emphasizing the potential peace of mind associated with completing screening. The second factor manipulates the type of exam highlighted in the outreach, randomly assigning participants to receive outreach focused on (i) cancer screening only, (ii) chronic disease testing only, or (iii) both cancer screening and chronic disease testing. Patients who have only one pending cancer exam are randomly assigned across the three message framing conditions only and are encouraged to get the cancer screening.

The experiment will test two sets of research questions.

Question 1. How does emphasizing different motivations for completing cancer screening affect patient engagement?

H1a. This study will test how messages emphasizing age-based health risks and the importance of early detection affect cancer screening engagement, relative to a basic message. Emphasizing health risks may increase perceived urgency and boost engagement; however, prior work on information avoidance suggests this framing may instead prompt avoidance of screening-related information and reduce engagement.

H1b. This study will test whether messages emphasizing that completing screening can bring peace of mind increase engagement relative to a basic message.

H1c. This study will test whether the effects of the two framing manipulations on cancer screening differ when the same messaging strategies are applied to chronic disease testing.

Question 2. How does combining recommendations for multiple preventive tests affect patient engagement? H2a. This study will examine the impact of bundling multiple tests (vs. single test) on patient engagement.

H2b. This study will test whether pairing cancer screening with a chronic disease testing recommendation affects cancer screening engagement. Recommending multiple tests may increase the perceived value of engaging with the healthcare system, boosting engagement with cancer screening; alternatively, patients may find the message more overwhelming or burdensome, reducing engagement with cancer screening.

H2c. This study will test whether pairing chronic disease testing with a cancer screening recommendation affects chronic disease testing engagement. Pairing may increase perceived value and make chronic disease testing seem less emotionally aversive, thus increasing engagement with chronic disease testing; alternatively, combining multiple recommendations may feel burdensome and reduce engagement with chronic disease testing.

The investigators will run ordinary least squares regressions (OLS) with robust standard errors to predict each outcome variable.

To test questions 1a and 1b, the study will focus on participants assigned to the cancer-screening-only condition, and the primary predictors of interest are indicators for whether participants are assigned to the Risk/Importance message condition or the Peace-of-Mind condition (with the Basic message condition as the reference group).

To test question 1c, the investigators will pool participants assigned to the cancer-screening-only and chronic-disease-only conditions and estimate models that include framing-condition indicators, an exam-type indicator, and their interactions.

To test question 2a, the investigators will focus on participants assigned to either cancer-screening-only condition, the chronic-disease-only condition, or the both-exams condition. The key independent variable will be an indicator for assignment to the both-exam condition (vs. the other two conditions combined as reference group). If this indicator is statistically significant, the investigators will compare the both-exam condition separately with cancer-screening-only condition and the chronic-disease-only condition.

To test question 2b, the study will focus on participants assigned to either the cancer-screening-only condition or the both-exams condition. The key independent variable will be an indicator for assignment to the both-exam condition.

To test question 2c, the study will focus on participants who received a message about chronic disease testing, including both those assigned to the chronic-disease-only condition and those assigned to the both-exams condition. The key independent variable will be an indicator for assignment to the both-exams condition.

Questions 1c-2c will only include participants with two exams pending (a cancer screening test and a chronic disease test for diabetes and dyslipidemia).

All regressions will be run with and without control variables, including number of pending exam fixed effects, age (continuous), gender, insurance type (public or private based on the local health insurance plans), and clinic or region indicators if available. For robustness, the investigators will conduct logit models as well.

Additionally, the study will explore whether the peace-of-mind message is more effective than the risk/importance message by comparing the coefficients on indicators for the risk/importance message and the peace-of-mind message in regressions described in the analysis.

Also, the investigators will examine whether the effects of the messaging manipulations on cancer screening engagement change when patients are simultaneously encouraged to complete both a cancer screening and chronic disease testing, relative to when they are only encouraged to complete a cancer screening. The regressions will include indicators for message types (risk/importance and peace of mind, relative to basic), an indicator for whether patients are recommended to take multiple tests (vs. just a cancer screening), and their interaction terms to predict (1) whether the patient indicates interest (by either clicking "Yes, I want help" or providing an equivalent affirmative response in Whatsapp) within 7 days, (2) whether the patient schedules the recommended cancer screening within 7 days, and (3) whether the patient completes the recommended cancer screening within 12 weeks.

Given that the experimental design addresses multiple distinct research questions, the analyses may ultimately be split across two papers focused on different sets of questions, particularly if including all analyses in a single paper would limit clarity or coherence.

The experiment is expected to last for 60 working days and reach 235,000 patients across all arms (including the standard-message arm that is not part of the study of interest). About 145,000 of these patients have two pending exams (cancer screening+chronic disease testing), and 90,000 patients have a pending cancer screening.

As an exploratory analysis, the investigators will examine patients' prior frequency of cancer and chronic disease screening as a potential moderator of intervention effects.

Being tested
Basic cancer screening message, Basic chronic disease test message, Basic combined message, Risk framing cancer screening message, Risk framing chronic disease test message
Keywords
Behavioral science, randomized controlled trial, WhatsApp patient outreach, message framing, information avoidance, cancer screening, chronic disease testing, preventive care
Medical subject headings
Breast Neoplasms, Uterine Cervical Neoplasms, Colorectal Neoplasms, Prostatic Neoplasms, Diabetes Mellitus, Dyslipidemias

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Basic cancer screening messageBehavioural

    Patients receive a WhatsApp message naming their recommended cancer screening exam and describing it as the test recommended for their age group.

  • Basic chronic disease test messageBehavioural

    Patients receive a WhatsApp message naming the recommended chronic disease test and describing it as the test recommended for their age group.

  • Basic combined messageBehavioural

    Patients receive a WhatsApp message naming both the recommended cancer screening and the chronic disease test, and describing them as the tests recommended for their age group.

  • Risk framing cancer screening messageBehavioural

    Patients receive a WhatsApp message naming their recommended cancer screening exam and emphasizing that (1) the recommendation is based on health risks common to their age group and (2) early detection can be life-saving

  • Risk framing chronic disease test messageBehavioural

    Patients receive a WhatsApp message naming the recommended chronic disease test and emphasizing that (1) the recommendation is based on health risks common to their age group and (2) early detection can be life-saving.

  • Risk framing combined messageBehavioural

    Patients receive a WhatsApp message naming both exams and emphasizing that (1) the recommendation is based on health risks common to their age group and (2) early detection can be life-saving.

  • Peace of mind framing cancer screening messageBehavioural

    Patients receive a WhatsApp message naming their recommended cancer screening exam and emphasizing that getting the exam done on time will give them peace of mind about their health.

  • Peace of mind framing chronic disease test messageBehavioural

    Patients receive a WhatsApp message naming the recommended chronic disease and emphasizing that getting the exam done on time will give them peace of mind about their health.

  • Peace of mind framing combined messageBehavioural

    Patients receive a WhatsApp message naming both exams and emphasizing that getting the exams done on time will give them peace of mind about their health.

Study groups in NCT07644910
Study groupRoleWhat they receive
Basic/Control × CancerActive comparatorBasic cancer screening message
Receives: Behavioral: Basic cancer screening message
Basic/Control × chronic disease testActive comparatorBasic chronic disease test message
Receives: Behavioral: Basic chronic disease test message
Basic/Control × BothActive comparatorBasic combined message
Receives: Behavioral: Basic combined message
Risk/Importance × CancerExperimentalRisk framing cancer screening message
Receives: Behavioral: Risk framing cancer screening message
Risk/Importance × Chronic Disease TestExperimentalRisk framing chronic disease test message
Receives: Behavioral: Risk framing chronic disease test message
Risk/Importance × BothExperimentalRisk framing combined message
Receives: Behavioral: Risk framing combined message
Peace of Mind × Cancer screeningExperimentalPeace of mind framing cancer screening message
Receives: Behavioral: Peace of mind framing cancer screening message
Peace of Mind × chronic disease TestExperimentalPeace of mind framing chronic disease test message
Receives: Behavioral: Peace of mind framing chronic disease test message
Peace of Mind × BothExperimentalPeace of mind framing combined message
Receives: Behavioral: Peace of mind framing combined message

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Screening Engagement Response

    Binary indicator of whether the patient clicks "Yes, I want help" or provides an equivalent affirmative response via WhatsApp within 7 days of receiving the message (1), or does not take either action (0). Used to test H1a, H1b, H1c, and H2a.

    Measured: 7 days after message delivery

  2. Cancer Screening Appointment

    Binary indicator of whether the patient schedules the recommended cancer screening exam within 7 days of receiving the message (1) or does not (0). Used to test H2b

    Measured: 7 days after message delivery

  3. Chronic Disease Testing Appointment

    Binary indicator of whether the patient schedules the recommended chronic disease test within 7 days of receiving the message (1) or does not (0). Used to test H2c.

    Measured: 7 days after message delivery

Secondary outcomes (6)
  1. Screening Appointment Scheduling

    Binary indicator of whether the patient schedules the specific test recommended in the message within 7 days of receiving it (1) or does not (0). Used to test H1a, H1b, and H1c.

    Measured: 7 days after message delivery

  2. Screening Test Completion

    Binary indicator of whether the patient completes the specific test recommended in the message within 12 weeks of receiving it (1) or does not (0). Used to test H1a, H1b, and H1c

    Measured: 12 weeks after message delivery

  3. Any Test Appointment Scheduling

    Binary indicator of whether the patient schedules any of the tests recommended in the message within 7 days of receiving it (1) or does not (0). Used to test H2a.

    Measured: 7 days after message delivery

  4. Any Test Completion

    Binary indicator of whether the patient completes any of the tests recommended in the message within 12 weeks of receiving it (1) or does not (0). Used to test H2a.

    Measured: 12 weeks after message delivery

  5. Cancer Screening Completion

    Binary indicator of whether the patient completes the recommended cancer screening exam within 12 weeks of receiving the message (1) or does not (0). Used to test H2b

    Measured: 12 weeks after message delivery

  6. Chronic Disease Test Completion

    Binary indicator of whether the patient completes the recommended chronic disease test within 12 weeks of receiving the message (1) or does not (0). Used to test H2c.

    Measured: 12 weeks after message delivery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Jun 2026
  2. Study start8 Jun 2026 (estimated)
  3. Primary completion8 Sep 2026 (estimated)
  4. Study completion8 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Factorial
Model description
Patients with two exams pending (a cancer screening test and a chronic disease test for diabetes and dyslipidemia) will be randomly assigned across a 3 × 3 factorial design: three message framing conditions (Basic, Risk/Importance, Peace of Mind) crossed with three exam-type conditions (cancer screening only, chronic disease test only, or both exams). Participants with only a cancer screening pending will be assigned to the 3 framing conditions and be encouraged to get the cancer screening. In both cases, participants are assigned to each experimental arm at twice the rate of an additional arm receiving the standard message currently used by the medical institution. This standard-message arm is included for operational purposes and is not part of the pre-specified analyses.
Masking
Single blind
Who is masked
Participant
Enrolment
235,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07644910
Sponsor's protocol ID
Message Framing for Screening
Status last verified
Jun 2026
First submitted
8 Jun 2026
Last updated
17 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Individual participant data will not be shared due to institutional restrictions that prohibit data disclosure, even in anonymized form

Questions about this trial

What is this clinical trial studying?

A study testing Basic cancer screening message, Basic chronic disease test message and Basic combined message in people with Breast Neoplasms and Uterine Cervical Neoplasms, run by University of Chile.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 17 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Daniel Schwartz Associate Professor, Department of Industrial Engineering, Ph.D. Behavioral Decision (+56979984165, daschwar@dii.uchile.cl), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Screening Engagement Response (time frame: 7 days after message delivery). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jun 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in